| 摘要 |
Disclosed is the use of a Wnt-binding agent that comprises: (a) a first polypeptide comprising SEQ ID NO:39, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:40, or SEQ ID NO:41; and (b) a second polypeptide comprising SEQ ID NO:42; wherein the first polypeptide is directly linked to the second polypeptide, for the manufacture of a medicament for the treatment of cancer, wherein the cancer is pancreatic cancer, hepatocellular cancer, or ovarian cancer (sequences as defined in the specification). |
